AngioDynamics (ANGO) Competitors

$10.77 -0.26 (-2.36%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$11.05 +0.28 (+2.60%)

As of 05/15/2026 07:57 PM Eastern

ANGO vs. TMO, WST, SMA, ATEC, and ATRC

Should you buy AngioDynamics stock or one of its competitors? MarketBeat compares AngioDynamics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AngioDynamics include Thermo Fisher Scientific (TMO), West Pharmaceutical Services (WST), Smartstop Self Storage REIT (SMA), Alphatec (ATEC), and AtriCure (ATRC).

How does AngioDynamics compare to Thermo Fisher Scientific?

AngioDynamics (NASDAQ:ANGO) and Thermo Fisher Scientific (NYSE:TMO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

AngioDynamics has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Comparatively, Thermo Fisher Scientific has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market.

Thermo Fisher Scientific has a net margin of 15.15% compared to AngioDynamics' net margin of -10.01%. Thermo Fisher Scientific's return on equity of 16.86% beat AngioDynamics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AngioDynamics	-10.01%	-4.66%	-3.08%
Thermo Fisher Scientific	15.15%	16.86%	8.15%

89.4% of AngioDynamics shares are owned by institutional investors. Comparatively, 89.2% of Thermo Fisher Scientific shares are owned by institutional investors. 6.0% of AngioDynamics shares are owned by insiders. Comparatively, 0.3% of Thermo Fisher Scientific shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

AngioDynamics presently has a consensus target price of $18.67, indicating a potential upside of 73.32%. Thermo Fisher Scientific has a consensus target price of $616.10, indicating a potential upside of 40.61%. Given AngioDynamics' higher probable upside, research analysts clearly believe AngioDynamics is more favorable than Thermo Fisher Scientific.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AngioDynamics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Thermo Fisher Scientific	0 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.96

Thermo Fisher Scientific has higher revenue and earnings than AngioDynamics. AngioDynamics is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AngioDynamics	$292.50M	1.52	-$33.99M	-$0.75	N/A
Thermo Fisher Scientific	$44.56B	3.65	$6.70B	$18.19	24.09

In the previous week, Thermo Fisher Scientific had 29 more articles in the media than AngioDynamics. MarketBeat recorded 31 mentions for Thermo Fisher Scientific and 2 mentions for AngioDynamics. Thermo Fisher Scientific's average media sentiment score of 1.25 beat AngioDynamics' score of 0.94 indicating that Thermo Fisher Scientific is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AngioDynamics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Thermo Fisher Scientific	24 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Thermo Fisher Scientific beats AngioDynamics on 14 of the 17 factors compared between the two stocks.

How does AngioDynamics compare to West Pharmaceutical Services?

AngioDynamics (NASDAQ:ANGO) and West Pharmaceutical Services (NYSE:WST) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

AngioDynamics has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Comparatively, West Pharmaceutical Services has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market.

West Pharmaceutical Services has a net margin of 16.85% compared to AngioDynamics' net margin of -10.01%. West Pharmaceutical Services' return on equity of 19.03% beat AngioDynamics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AngioDynamics	-10.01%	-4.66%	-3.08%
West Pharmaceutical Services	16.85%	19.03%	14.06%

89.4% of AngioDynamics shares are owned by institutional investors. Comparatively, 93.9% of West Pharmaceutical Services shares are owned by institutional investors. 6.0% of AngioDynamics shares are owned by insiders. Comparatively, 0.6% of West Pharmaceutical Services shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

AngioDynamics presently has a consensus target price of $18.67, indicating a potential upside of 73.32%. West Pharmaceutical Services has a consensus target price of $322.89, indicating a potential upside of 6.53%. Given AngioDynamics' higher probable upside, research analysts clearly believe AngioDynamics is more favorable than West Pharmaceutical Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AngioDynamics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
West Pharmaceutical Services	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.92

West Pharmaceutical Services has higher revenue and earnings than AngioDynamics. AngioDynamics is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AngioDynamics	$292.50M	1.52	-$33.99M	-$0.75	N/A
West Pharmaceutical Services	$3.07B	6.97	$493.70M	$7.48	40.52

In the previous week, West Pharmaceutical Services had 13 more articles in the media than AngioDynamics. MarketBeat recorded 15 mentions for West Pharmaceutical Services and 2 mentions for AngioDynamics. AngioDynamics' average media sentiment score of 0.94 beat West Pharmaceutical Services' score of 0.68 indicating that AngioDynamics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AngioDynamics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
West Pharmaceutical Services	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

West Pharmaceutical Services beats AngioDynamics on 14 of the 17 factors compared between the two stocks.

How does AngioDynamics compare to Smartstop Self Storage REIT?

AngioDynamics (NASDAQ:ANGO) and Smartstop Self Storage REIT (NYSE:SMA) are both small-cap health care equipment companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

89.4% of AngioDynamics shares are owned by institutional investors. 6.0% of AngioDynamics shares are owned by insiders. Comparatively, 5.5% of Smartstop Self Storage REIT shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Smartstop Self Storage REIT has lower revenue, but higher earnings than AngioDynamics. AngioDynamics is trading at a lower price-to-earnings ratio than Smartstop Self Storage REIT, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AngioDynamics	$292.50M	1.52	-$33.99M	-$0.75	N/A
Smartstop Self Storage REIT	$281.14M	5.83	-$1.55M	$0.15	197.30

In the previous week, AngioDynamics and AngioDynamics both had 2 articles in the media. AngioDynamics' average media sentiment score of 0.94 beat Smartstop Self Storage REIT's score of 0.65 indicating that AngioDynamics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AngioDynamics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Smartstop Self Storage REIT	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Smartstop Self Storage REIT has a net margin of 4.38% compared to AngioDynamics' net margin of -10.01%. Smartstop Self Storage REIT's return on equity of 1.00% beat AngioDynamics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AngioDynamics	-10.01%	-4.66%	-3.08%
Smartstop Self Storage REIT	4.38%	1.00%	0.54%

AngioDynamics presently has a consensus target price of $18.67, indicating a potential upside of 73.32%. Smartstop Self Storage REIT has a consensus target price of $36.94, indicating a potential upside of 24.83%. Given AngioDynamics' higher possible upside, equities analysts plainly believe AngioDynamics is more favorable than Smartstop Self Storage REIT.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AngioDynamics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Smartstop Self Storage REIT	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.73

Summary

Smartstop Self Storage REIT beats AngioDynamics on 10 of the 15 factors compared between the two stocks.

How does AngioDynamics compare to Alphatec?

Alphatec (NASDAQ:ATEC) and AngioDynamics (NASDAQ:ANGO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

Alphatec has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, AngioDynamics has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market.

AngioDynamics has lower revenue, but higher earnings than Alphatec. AngioDynamics is trading at a lower price-to-earnings ratio than Alphatec, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alphatec	$764.16M	1.54	-$143.36M	-$0.82	N/A
AngioDynamics	$292.50M	1.52	-$33.99M	-$0.75	N/A

In the previous week, Alphatec had 22 more articles in the media than AngioDynamics. MarketBeat recorded 24 mentions for Alphatec and 2 mentions for AngioDynamics. AngioDynamics' average media sentiment score of 0.94 beat Alphatec's score of 0.01 indicating that AngioDynamics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alphatec	4 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	4 Very Negative mention(s)	Neutral
AngioDynamics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alphatec presently has a consensus target price of $18.58, indicating a potential upside of 142.60%. AngioDynamics has a consensus target price of $18.67, indicating a potential upside of 73.32%. Given Alphatec's stronger consensus rating and higher possible upside, equities research analysts plainly believe Alphatec is more favorable than AngioDynamics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alphatec	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
AngioDynamics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

66.4% of Alphatec shares are owned by institutional investors. Comparatively, 89.4% of AngioDynamics shares are owned by institutional investors. 13.5% of Alphatec shares are owned by company insiders. Comparatively, 6.0% of AngioDynamics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

AngioDynamics has a net margin of -10.01% compared to Alphatec's net margin of -15.93%. AngioDynamics' return on equity of -4.66% beat Alphatec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alphatec	-15.93%	-1,183.84%	-15.83%
AngioDynamics	-10.01%	-4.66%	-3.08%

Summary

Alphatec beats AngioDynamics on 9 of the 17 factors compared between the two stocks.

How does AngioDynamics compare to AtriCure?

AngioDynamics (NASDAQ:ANGO) and AtriCure (NASDAQ:ATRC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

AngioDynamics currently has a consensus target price of $18.67, indicating a potential upside of 73.32%. AtriCure has a consensus target price of $48.71, indicating a potential upside of 73.24%. Given AngioDynamics' higher probable upside, equities analysts plainly believe AngioDynamics is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AngioDynamics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
AtriCure	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

AngioDynamics has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market. Comparatively, AtriCure has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market.

89.4% of AngioDynamics shares are held by institutional investors. Comparatively, 99.1% of AtriCure shares are held by institutional investors. 6.0% of AngioDynamics shares are held by insiders. Comparatively, 4.0% of AtriCure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

AtriCure has a net margin of -0.83% compared to AngioDynamics' net margin of -10.01%. AtriCure's return on equity of 0.29% beat AngioDynamics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AngioDynamics	-10.01%	-4.66%	-3.08%
AtriCure	-0.83%	0.29%	0.22%

AtriCure has higher revenue and earnings than AngioDynamics. AtriCure is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AngioDynamics	$292.50M	1.52	-$33.99M	-$0.75	N/A
AtriCure	$534.53M	2.66	-$11.45M	-$0.10	N/A

In the previous week, AtriCure had 4 more articles in the media than AngioDynamics. MarketBeat recorded 6 mentions for AtriCure and 2 mentions for AngioDynamics. AngioDynamics' average media sentiment score of 0.94 beat AtriCure's score of 0.92 indicating that AngioDynamics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AngioDynamics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AtriCure	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

AtriCure beats AngioDynamics on 13 of the 17 factors compared between the two stocks.

Get AngioDynamics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANGO vs. The Competition

Export

Metric	AngioDynamics	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$445.01M	$6.75B	$6.38B	$12.30B
Dividend Yield	N/A	1.76%	2.81%	5.27%
P/E Ratio	-14.36	49.11	20.62	25.25
Price / Sales	1.52	68.23	554.15	76.57
Price / Cash	22.11	23.95	42.43	54.86
Price / Book	2.39	6.49	9.87	6.90
Net Income	-$33.99M	$158.34M	$3.57B	$334.66M
7 Day Performance	-3.84%	-2.95%	0.23%	0.12%
1 Month Performance	-0.83%	-6.28%	-2.54%	-0.18%
1 Year Performance	14.57%	-4.45%	33.54%	30.62%

AngioDynamics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANGO AngioDynamics	2.8273 of 5 stars	$10.77 -2.4%	$18.67 +73.3%	+14.6%	$445.01M	$292.50M	N/A	760	Positive News
TMO Thermo Fisher Scientific	4.7728 of 5 stars	$462.46 -1.4%	$623.05 +34.7%	+6.3%	$174.37B	$44.56B	25.42	125,000	Positive News Analyst Upgrade
WST West Pharmaceutical Services	4.0993 of 5 stars	$300.27 -0.1%	$322.89 +7.5%	+40.1%	$21.24B	$3.07B	40.14	10,800	Trending News Analyst Upgrade Analyst Revision
SMA Smartstop Self Storage REIT	3.5907 of 5 stars	$30.30 -3.3%	$36.94 +21.9%	-19.3%	$1.73B	$281.14M	N/A	N/A
ATEC Alphatec	3.7884 of 5 stars	$10.33 -1.0%	$22.82 +120.9%	-40.9%	$1.60B	$764.16M	N/A	700	Trending News Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANGO) was last updated on 5/17/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AngioDynamics (ANGO) Competitors

ANGO vs. TMO, WST, SMA, ATEC, and ATRC

How does AngioDynamics compare to Thermo Fisher Scientific?

Summary

How does AngioDynamics compare to West Pharmaceutical Services?

Summary

How does AngioDynamics compare to Smartstop Self Storage REIT?

Summary

How does AngioDynamics compare to Alphatec?

Summary

How does AngioDynamics compare to AtriCure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANGO vs. The Competition

AngioDynamics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AngioDynamics (ANGO) Competitors

ANGO vs. TMO, WST, SMA, ATEC, and ATRC

How does AngioDynamics compare to Thermo Fisher Scientific?

Which has more risk & volatility, ANGO or TMO?

Is ANGO or TMO more profitable?

Do insiders & institutionals believe in ANGO or TMO?

Do analysts rate ANGO or TMO?

Which has preferable earnings & valuation, ANGO or TMO?

Does the media favor ANGO or TMO?

Summary

How does AngioDynamics compare to West Pharmaceutical Services?

Which has more risk & volatility, ANGO or WST?

Is ANGO or WST more profitable?

Do insiders & institutionals believe in ANGO or WST?

Do analysts rate ANGO or WST?

Which has preferable earnings & valuation, ANGO or WST?

Does the media favor ANGO or WST?

Summary

How does AngioDynamics compare to Smartstop Self Storage REIT?

Do insiders & institutionals believe in ANGO or SMA?

Which has better valuation and earnings, ANGO or SMA?

Does the media prefer ANGO or SMA?

Is ANGO or SMA more profitable?

Do analysts rate ANGO or SMA?

Summary

How does AngioDynamics compare to Alphatec?

Which has more risk and volatility, ATEC or ANGO?

Which has stronger valuation & earnings, ATEC or ANGO?

Does the media refer more to ATEC or ANGO?

Do analysts recommend ATEC or ANGO?

Do institutionals & insiders believe in ATEC or ANGO?

Is ATEC or ANGO more profitable?

Summary

How does AngioDynamics compare to AtriCure?

Do analysts rate ANGO or ATRC?

Which has more risk and volatility, ANGO or ATRC?

Do insiders and institutionals have more ownership in ANGO or ATRC?

Is ANGO or ATRC more profitable?

Which has preferable valuation & earnings, ANGO or ATRC?

Does the media prefer ANGO or ATRC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANGO vs. The Competition

AngioDynamics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools